Dalfampridine, commonly known as Ampyra, is an oral medication utilized in the treatment of multiple sclerosis (MS). While its precise mechanism of action remains unknown, it is recognized for impeding the movement of potassium between nerve cells. Animal studies have indicated an enhancement in the conduction of nerve signals. The FDA approved Ampyra in December 1987.
Brand Names and Generic Availability
Ampyra is the primary brand name associated with dalfampridine, and as of now, there is no generic equivalent available.
Prescription Requirement
Dalfampridine, sold under the brand name Ampyra, necessitates a prescription for acquisition.
Common and Serious Side Effects of Dalfampridine
The most prevalent side effect linked to Ampyra is urinary tract infections. Additionally, users may experience common side effects such as nausea, insomnia, dizziness, headaches, and back pain. It is crucial to be aware of potential serious side effects, including seizures and severe allergic reactions (anaphylaxis). Individuals with a history of seizures should refrain from using Ampyra. Signs of anaphylaxis encompass difficulty breathing, itching, and swelling of the throat or tongue.
Dalfampridine Dosage Guidelines
The recommended maximum dose for dalfampridine (Ampyra) is 10 mg twice daily, with or without food, approximately 12 hours apart. It is imperative not to divide, crush, chew, or dissolve the tablets.
Interactions with Other Drugs or Supplements
As of now, there have been no identified drug interactions associated with Ampyra.
Safety during Pregnancy and Breastfeeding
There is a lack of adequate studies on the effects of Ampyra in pregnant women. The excretion of Ampyra in human milk is not well-established, necessitating caution for breastfeeding individuals.
Dalfampridine Storage Information
Ampyra should be stored at room temperature, ranging from 15°C to 30°C (59°F to 86°F).
In Brief
Dalfampridine (Ampyra) serves as a prescribed medication to enhance walking ability in patients grappling with multiple sclerosis (MS). Prior to commencing this treatment, it is essential to thoroughly review potential side effects, interactions, and safety considerations, particularly during pregnancy and breastfeeding.